Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Rheumatol. 2007 Jul;19(4):370-5.

An update on glucocorticoid-induced osteoporosis.

Author information

1
Institute of Health and Social Care Research, Peninsula Medical School, Universities of Exeter and Plymouth and Duchess of Cornwall Centre for Osteoporosis, Department of Rheumatology, Royal Cornwall Hospital, Truro, UK. anthony.woolf@btopenworld.com

Abstract

PURPOSE OF REVIEW:

Glucocorticoids are widely used, often long term, and a major side effect is osteoporosis and increased risk of fracture. This review considers how common is the problem, the patients who are most at risk, our current understanding of mechanisms, and how to prevent and effectively treat glucocorticoid-induced osteoporosis. The actions currently being undertaken in clinical practice are reviewed.

RECENT FINDINGS:

Glucocorticoid-induced osteoporosis is an increasing problem that occurs not only in those on high-dose therapy. Advances in our knowledge of the cellular and cytokine mechanisms of bone turnover and glucocorticoid mechanisms of action are leading to a better understanding of how glucocorticoids affect bone cells and novel ways of prevention. Although there are effective treatments to prevent and control glucocorticoid-induced osteoporosis as well as guidelines for their use, they are still not being applied in routine clinical practice.

SUMMARY:

Glucocorticoid-induced osteoporosis is a significant problem. Although our understanding of effective prevention and treatment strategies is improving, there needs to be better implementation of these strategies.

PMID:
17551369
DOI:
10.1097/BOR.0b013e328133f5c7
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wolters Kluwer
    Loading ...
    Support Center